David J Seiden

Learn More
BACKGROUND AND PURPOSE To assess the efficacy and safety of ramelteon, a selective MT(1)/MT(2) receptor agonist, for chronic insomnia treatment. PATIENTS AND METHODS Randomized, double-blind, placebo-controlled 35-night outpatient trial with weekly clinic visits at multiple centers. Patients include older adults (>or=65 years; N=829) with chronic(More)
BACKGROUND AND PURPOSE To evaluate the efficacy, safety, and dose response of Ramelteon, a novel highly selective MT1/MT2 receptor agonist, in patients with chronic primary insomnia. PATIENTS AND METHODS A randomized, multicenter, double-blind, placebo-controlled, five-period crossover study design was performed. A total of 107 patients, aged 18-64 years,(More)
We retrospectively analyzed night-to-night variability in the indices of sleep apnea in a group of men who underwent consecutive polysomnograms (PSGs) in the evaluation of impotence. The study group consisted of 37 subjects. Fifty-seven percent of the subjects had an apnea/hypopnea index (AHI) of 5 or more on the first PSG, whereas 70% met this criterion on(More)
OBJECTIVE To assess the efficacy and safety of ramelteon, a selective melatonin MT1/MT2-receptor agonist, for insomnia treatment in older adults. METHODS In a randomized, 9-week, 3-period crossover trial conducted at 17 sleep centers, older adults (N = 100) with chronic primary insomnia (37 men, 63 women; mean age [range], 70.7 [65-83] years) were(More)
STUDY OBJECTIVES To evaluate the efficacy and safety of doxepin 1, 3, and 6 mg in insomnia patients. DESIGN Adults (18-64 y) with chronic primary insomnia (DSM-IV) were randomly assigned to one of four sequences of 1 mg, 3 mg, and 6 mg of doxepin, and placebo in a crossover study. Treatment periods consisted of 2 polysomnographic assessment nights with a(More)
STUDY OBJECTIVES Evaluate the efficacy of eszopiclone in primary insomnia. DESIGN/SETTING Randomized, double-blind, placebo-controlled multicenter in outpatient setting with weekly visits. PARTICIPANTS Two-hundred thirty one men and women aged 65 to 85 years (mean age 72.3 years) with primary insomnia, as defined by the Diagnostic and Statistical Manual(More)
OBJECTIVE This study examined the effect of armodafinil on late-in-shift clinical condition, wakefulness, and overall functioning of patients with shift work disorder. METHODS Patients with clinically diagnosed shift work disorder received armodafinil or placebo on nights worked for 6 weeks. Patients included in the study experienced late-in-shift(More)
INTRODUCTION Insomnia is a condition affecting 10% to 15% of the adult population and is characterized by difficulty falling asleep, difficulty staying asleep, or nonrestorative sleep, accompanied by daytime impairment or distress. This study evaluates APD125, a selective inverse agonist of the 5-HT(2A) receptor, for treatment of chronic insomnia, with(More)
STUDY OBJECTIVE Indiplon is a nonbenzodiazepine GABA potentiator, which exhibits pharmacologic selectivity for GABA(A) receptors containing the alpha1 subunit. The aim of the present study was to evaluate the efficacy and safety of a 15-mg nightly dose of modified-release indiplon tablets in elderly patients with primary insomnia characterized by(More)
OBJECTIVE To examine whether treatment with armodafinil for 6 weeks affected patient-reported overall functioning and daily quality of life compared with placebo in patients with excessive sleepiness associated with shift work disorder. METHOD This 6-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study was conducted in 45(More)